Patent ID: 11903984
Assignee: PHI THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 6:
7. The composition of claim 1, further comprising a probiotic bacterium, P. acnes bacterium comprising at least one of the following characteristics:
(a) comprises a 16S rDNA sequence with a T992C mutation compared to the KPA171202 type strain 16S rDNA sequence set forth as SEQ ID NO: 2;
(b) comprises a 16S rDNA sequence with a T838C mutation compared to the KPA171202 type strain 16S rDNA sequence set forth as SEQ ID NO: 2;
(c) comprises a 16S rDNA sequence with a C1322T mutation compared to the KPA171202 type strain 16S rDNA sequence set forth as SEQ ID NO: 2;
(d) comprises a 16S rDNA sequence with a C986T mutation compared to the KPA171202 type strain 16S rDNA sequence set forth as SEQ ID NO: 2;
(e) comprises a 16S rDNA sequence that is identical to the sequence of SEQ ID NO: 3;
(f) comprises a 16S rDNA sequence that is identical to the sequence of SEQ ID NO: 4;
(g) does not comprise a linear plasmid;
(h) does not comprise a plasmid that comprises a virulence factor;
(i) does not comprises a plasmid that encodes an extrachromosomal lipase and/or a tight adhesion virulence factor;
(j) produces less than about 20% of the level of lipase that is produced by a pathogenic P. acnes strain when grown in a planktonic culture;
(k) produces less than about 10% of the level of lipase that is produced by a pathogenic P. acnes strain when grown in an adherent culture;
(l) adheres to epithelial cells at least 50% less than a pathogenic P. acnes strain; or
(m) is less inflammatory than a pathogenic P. acnes strain.